Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

996 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL, Pardanani A, Tefferi A, Gilliland DG. Levine RL, et al. Among authors: tefferi a. Nat Rev Cancer. 2007 Sep;7(9):673-83. doi: 10.1038/nrc2210. Nat Rev Cancer. 2007. PMID: 17721432 Review.
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. Cools J, et al. Among authors: tefferi a. N Engl J Med. 2003 Mar 27;348(13):1201-14. doi: 10.1056/NEJMoa025217. N Engl J Med. 2003. PMID: 12660384
The forgotten myeloproliferative disorder: myeloid metaplasia.
Tefferi A. Tefferi A. Oncologist. 2003;8(3):225-31. doi: 10.1634/theoncologist.8-3-225. Oncologist. 2003. PMID: 12773744 Review.
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A, Tefferi A. Pardanani A, et al. Among authors: tefferi a. Leuk Res. 2004 May;28 Suppl 1:S47-52. doi: 10.1016/j.leukres.2003.10.006. Leuk Res. 2004. PMID: 15036941 Review.
Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates.
Sirhan S, Lasho TL, Elliott MA, Tefferi A. Sirhan S, et al. Among authors: tefferi a. Haematologica. 2005 Mar;90(3):406-8. Haematologica. 2005. PMID: 15749676
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Levine RL, et al. Among authors: tefferi a. Cancer Cell. 2005 Apr;7(4):387-97. doi: 10.1016/j.ccr.2005.03.023. Cancer Cell. 2005. PMID: 15837627
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. Steensma DP, et al. Among authors: tefferi a. Blood. 2005 Aug 15;106(4):1207-9. doi: 10.1182/blood-2005-03-1183. Epub 2005 Apr 28. Blood. 2005. PMID: 15860661 Free PMC article.
JAK2 in myeloproliferative disorders is not just another kinase.
Tefferi A, Gilliland DG. Tefferi A, et al. Cell Cycle. 2005 Aug;4(8):1053-6. Epub 2005 Aug 26. Cell Cycle. 2005. PMID: 15970705
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Tefferi A, Gilliland DG. Tefferi A, et al. Mayo Clin Proc. 2005 Jul;80(7):947-58. doi: 10.4065/80.7.947. Mayo Clin Proc. 2005. PMID: 16007902 Review.
Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
Lasho TL, Mesa R, Gilliland DG, Tefferi A. Lasho TL, et al. Among authors: tefferi a. Br J Haematol. 2005 Sep;130(5):797-9. doi: 10.1111/j.1365-2141.2005.05682.x. Br J Haematol. 2005. PMID: 16115143 No abstract available.
996 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback